Xsulin 50/50 Injection is a premixed formulation containing human insulin at a concentration of 100 IU/mL, designed for the management of diabetes mellitus requiring insulin therapy. This biphasic insulin preparation comprises 50% soluble (regular) insulin and 50% intermediate-acting insulin, providing both rapid onset and sustained glycemic control. The soluble insulin component facilitates prompt reduction of postprandial blood glucose levels, while the intermediate-acting portion ensures prolonged basal insulin coverage, thereby minimizing fluctuations in blood glucose throughout the day. Xsulin 50/50 is indicated for adult and pediatric patients with type 1 diabetes mellitus and for those with type 2 diabetes mellitus inadequately controlled by diet, exercise, and oral hypoglycemic agents alone. Administration is typically via subcutaneous injection, with dosing individualized based on patient-specific factors including blood glucose monitoring results, lifestyle, and concurrent medical conditions. Proper injection technique and rotation of injection sites are essential to optimize absorption and reduce the risk of lipodystrophy. Patients should be educated on recognizing and managing hypoglycemia, a potential adverse effect. Xsulin 50/50 Injection should be stored under recommended conditions to maintain potency and efficacy. It is contraindicated in patients with hypoglycemia or hypersensitivity to human insulin or any excipients.